MedTrace Logo

carDIo-ttranSSfOrm nucLEar Imaging Study

NCT05259072 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2025-01-29

No results posted yet for this study

Summary

The investigators will evaluate the change in myocardial uptake of 99m-technetium pyrophosphate (Tc-99m PYP) tracer on serial planar and SPECT imaging in patients enrolled in the CARDIO-TTRansform clinical trial (NCT04136171).

Conditions

  • Amyloidosis
  • Transthyretin Amyloid Cardiomyopathy

Interventions

DIAGNOSTIC_TEST

99m-technetium pyrophosphate scintigraphy

Imaging test

Sponsors & Collaborators

  • Ionis Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Ahmad Masri, MD MS · Oregon Health and Science University

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-19
Primary Completion
2023-12-30
Completion
2023-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05259072 on ClinicalTrials.gov